Neuropeptide Y

What it is

Neuropeptide Y is the most abundant signaling peptide in the human brain, playing a central role in hunger regulation, stress resilience, anxiety dampening, and cardiovascular tone. Researchers study it for its potential in treating PTSD, epilepsy, obesity, and stroke recovery. No approved NPY drug exists yet, but NPY receptor-targeting agents are in development.

The scientific side

neuropeptide Y (NPY) is a 36-amino acid peptide that functions as both a sympathetic neurotransmitter and a neuromodulator, distributed throughout the peripheral and central nervous systems. Its biological actions are mediated through a family of G-protein-coupled receptors — Y1, Y2, Y4, Y5, and Y6 — each with distinct downstream signaling profiles and anatomical distributions. This receptor diversity explains the wide breadth of physiological functions attributed to NPY. In the hypothalamus, NPY is co-expressed in neurons alongside agouti-related peptide (AgRP) within the arcuate nucleus and acts as a potent orexigenic signal: NPY/AgRP neurons sense circulating leptin and other metabolic cues and regulate gonadotropin-releasing hormone (GnRH) neuron activity, linking energy balance to reproductive function. In obesity, elevated NPY/AgRP activity can suppress GnRH pulsatility, contributing to ovulatory dysfunction. In the limbic system and brainstem, NPY exerts anxiolytic effects primarily through Y1 receptor activation, reducing activity in fear-circuitry nodes including the amygdala, locus coeruleus, and hippocampus. Conversely, Y2 receptor activation tends to be anxiogenic, underscoring the bidirectional complexity of the NPY system. Under conditions of traumatic stress, insufficient central NPY signaling has been associated with impaired coping and vulnerability to PTSD-like phenotypes; polymorphisms in the NPY gene have been shown to predict impaired stress processing in humans. In the cardiovascular system, NPY acts as a potent vasoconstrictor via Y1 receptors on vascular smooth muscle, and elevated circulating NPY after acute ischaemic stroke predicts worse clinical outcomes including death and major disability at 12 months in large prospective human cohorts. In cancer biology, NPY activates Y1R, Y2R, and Y5R on tumor cells and endothelium, promoting cell proliferation, angiogenesis, invasion, and metastasis through multiple intracellular signaling cascades. In bone, osteocyte-derived NPY promotes adipogenesis and suppresses osteogenesis in bone marrow stem cells. In epilepsy, endogenous NPY released during seizure discharges suppresses excitatory network activity via Y2 and Y5 receptors; Y1 blockade is also anticonvulsant in animal models, motivating drug development for refractory epilepsy. NPY's pleiotropic roles across appetite, mood, stress, cardiovascular, oncological, and skeletal systems make it a compelling but complex pharmacological target.

Class: Endogenous neuropeptide — 36-amino acid peptide; sympathetic neurotransmitter and neuromodulator; member of the pancreatic polypeptide (PP) superfamily

What it's studied for

• PTSD and stress resilience — potential therapeutic target Human observational
• Appetite regulation and obesity — role of hypothalamic NPY/AgRP signaling Human observational
• Epilepsy — anticonvulsant mechanism and receptor-targeted drug development Animal studies only
• Ischaemic stroke — circulating NPY as a prognostic biomarker Human observational
• Anxiety and depression — endogenous anxiolytic role Human observational
• Cancer biology — NPY system in tumor growth and metastasis Mechanistic only
• Fibromyalgia and chronic pain-stress interface Human observational
• Bone metabolism — NPY regulation of bone-fat balance and osteoporosis Animal studies only

Safety signals

• Cardiovascular vasoconstriction and hypertension risk — NPY is a potent endogenous vasoconstrictor
• Orexigenic effect — potent stimulation of appetite and potential for weight gain
• Reproductive axis suppression — NPY inhibits GnRH pulsatility
• Potential anxiogenic effects via Y2 receptor activation
• Promotion of tumor angiogenesis and growth — oncological risk in cancer-susceptible individuals
• Blood-brain barrier impermeability of exogenous NPY — risk of off-target peripheral effects without CNS benefit
• Interaction with stress axis and HPA function — unpredictable effects in PTSD and trauma populations

Community-reported dosing

No peer-reviewed studies indexed for this peptide yet.